<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01208662</url>
  </required_header>
  <id_info>
    <org_study_id>10-106</org_study_id>
    <nct_id>NCT01208662</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65</brief_title>
  <acronym>DFCI 10-106</acronym>
  <official_title>A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Sloan-Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The drugs, lenalidomide, bortezomib, and dexamethasone, are approved by the FDA.  They have
      not been approved in the combination for multiple myeloma or any other type of cancer.
      Bortezomib is currently approved by the FDA for the treatment of multiple myeloma.
      Lenalidomide is approved for use with dexamethasone for patients with multiple myeloma who
      have received at least one prior therapy and for the treatment of certain types of
      myelodysplastic syndrome (another type of cancer affecting the blood).  Dexamethasone is
      commonly used, either alone, or in combination with other drugs, to treat multiple myeloma.
      Melphalan and cyclophosphamide, the drugs used during stem cell collection and transplant,
      are also approved by the FDA.  Melphalan is an FDA-approved chemotherapy for multiple
      myeloma and is used as a high-dose conditioning treatment prior to stem cell
      transplantation.  Cyclophosphamide is used, either alone, or in combination with other
      drugs, to treat multiple myeloma.  These drugs have been used in other multiple myeloma
      studies and information from those studies suggests that this combination of therapy may
      help to treat newly diagnosed multiple myeloma.

      In this research study, we are looking to explore the drug combination, lenalidomide,
      bortezomib and dexamethasone alone or when combined with autologous stem cell
      transplantation to see what side effects it may have and how well it works for treatment of
      newly diagnosed multiple myeloma.  Specifically, the objective of this trial is to determine
      if, in the era of novel drugs, high dose therapy (HDT) is still necessary in the initial
      management of multiple myeloma in younger patients.  In this study, HDT as compared to
      conventional dose treatment would be considered superior if it significantly prolongs
      progression-free survival by at least 9 months or more, recognizing that particular
      subgroups may benefit more compared to others.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After screening procedures determine if a patient is eligible for this research study, the
      patient will be randomized into one of the study groups: lenalidomide, bortezomib and
      dexamethasone without autologous stem cell transplantation, followed by lenalidomide
      maintenance (Arm A) or lenalidomide, bortezomib and dexamethasone with autologous stem cell
      transplantation, followed by lenalidomide maintenance (Arm B).  There is an equal chance of
      being placed in either group.

      All participants will receive one cycle of lenalidomide, bortezomib and dexamethasone
      treatment before being randomized to Arm A or Arm B.

      Participants in Arm A will receive two additional cycles of lenalidomide, bortezomib and
      dexamethasone prior to stem cell collection.  If randomized to Arm A, the subject will
      undergo stem cell collection, followed by five cycles of lenalidomide, bortezomib and
      dexamethasone.  This will be followed by twelve months of lenalidomide treatment.

      Participants in Arm B will receive two additional cycles of lenalidomide, bortezomib and
      dexamethasone prior to stem cell collection.  If randomized to Arm B, the subject will
      undergo stem cell collection and autologous stem cell transplantation, followed by two
      cycles of lenalidomide, bortezomib and dexamethasone.  This will be followed by twelve
      months of lenalidomide treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Primary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare progression-free survival (PFS) between Arm A and Arm B.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the response rates (RR) between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare time to progression (TTP) between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the overall survival (OS) between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To compare toxicity between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>To define genetic prognostic groups evaluateed by gene expression profiling (GEP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcomes</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>To examine the best treatment in each GEP-defined prognostic group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare quality of life (QOL) between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>To collect medical resource utilization (MRU) information which may be used in economic evaluation models.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>High Dose Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lenalidomide, bortezomib, dexamethasone. Stem cell collection. Maintenance Lenalidomide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Treatment with SCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide, bortezomib, dexamethasone. Stem cell collection. Autologous Stem Cell Transplant. Maintenance Lenalidomide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Oral, 25 mg/day, days 1-14 for 8 total cycles for Arm A. Oral, 25 mg/day, days 1-14 for 5 total cycles for Arm B.
Oral, 10-15 mg/day, daily for 12 months in maintenance for Arm A and Arm B.</description>
    <arm_group_label>High Dose Treatment</arm_group_label>
    <arm_group_label>High Dose Treatment with SCT</arm_group_label>
    <other_name>CC-5013</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>IV, days 1, 4, 8 and 11 for 8 total cycles for Arm A. IV, days 1, 4, 8 and 11 for 5 total cycles for Arm B.</description>
    <arm_group_label>High Dose Treatment</arm_group_label>
    <arm_group_label>High Dose Treatment with SCT</arm_group_label>
    <other_name>PS-341</other_name>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Oral, days 1, 2, 4, 5, 8, 9, 11 and 12 for 8 total cycles for Arm A. Oral, days 1, 2, 4, 5, 8, 9, 11 and 12 for 5 total cycles for Arm B.
Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles.</description>
    <arm_group_label>High Dose Treatment</arm_group_label>
    <arm_group_label>High Dose Treatment with SCT</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Stem Cell Transplant</intervention_name>
    <description>Stem cell transplant</description>
    <arm_group_label>High Dose Treatment with SCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Multiple Myeloma, according to the International Myeloma Foundation 2003
             Diagnostic Criteria

          -  Documented symptomatic myeloma, with organ damage related to myeloma with laboratory
             assessments performed within 21 days of registration

          -  Myeloma that is measurable by either serum or urine evaluation of the monoclonal
             component or by assay of serum free light chains.

          -  ECOG performance status &lt;/= 2

          -  Negative HIV blood test

          -  Voluntary written informed consent

        Exclusion Criteria:

          -  Pregnant or lactating female

          -  Prior systemic therapy for MM (localized radiotherapy allowed if &gt;/= 2 weeks before
             study entry, corticosteroids allowed if dose &lt;/= equivalent of 160 mg dexamethasone
             over 2 weeks)

          -  Primary amyloidosis (AL) or myeloma complicated by amylosis

          -  Receiving any other investigational agents

          -  Known brain metastases

          -  Poor tolerability or allergy to any of the study drugs or compounds of similar
             composition

          -  Platelet count &lt;50,000/mm3, within 21 days of registration

          -  ANC &lt;1,000 cells/mm3, within 21 days of registration

          -  Hemoglobin &lt;8 g/dL, within 21 days of registration

          -  Hepatic impairment (&gt;/= 1.5 x institutional ULN or AST (SGOT), ALT (SGPT), or
             alkaline phosphatase &gt;2 x ULN). Patients with benign hyperbilirubinemia are eligible.

          -  Renal insufficiency (serum creatinine &gt;2.5 mg/dl or creatinine clearance &lt;60 ml/min,
             within 21 days of registration)

          -  Respiratory compromise (DLCO &lt; 50%)

          -  Clinical signs of heart or coronary failure or LVEF &lt; 40%.  Myocardial infarction
             within 6 months prior to enrollment, NYHA Class III or IV heart failure, uncontrolled
             angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence
             of acute ischemia or active conductive system abnormalities

          -  Intercurrent illness including, but not limited to ongoing or active severe
             infection, known infection with hepatitis B or C virus, poorly controlled diabetes,
             severe uncontrolled psychiatric disorder or psychiatric illness/social situations
             that would limit compliance with study requirements

          -  Previous history of another malignant condition except for basal cell carcinoma and
             stage I cervical cancer

          -  Inability to comply with an anti-thrombotic treatment regimen

          -  Peripheral neuropathy &gt;/= Grade 2
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul G. Richardson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul G Richardson, MD</last_name>
    <phone>617-632-2104</phone>
    <email>paul_richardson@dfci.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Richardson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noopur Raje, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Avigan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Zonder, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jeffrey Zonder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Radhakrishnan Ramchandren, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Schiffer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Runge-Morris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abhinav Deol, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Voorhees, MD</last_name>
    </contact>
    <investigator>
      <last_name>Peter Voorhees, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Wood Jr, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hendrik van Deventer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Shea, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Serody, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefanie Sarantopoulos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristy Richards, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Park, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Don Gabriel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Foster, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Armistead, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Gasparetto, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cristina Gasparetto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Beaven, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nelson Chao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Chute, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos de Castro III, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis Diehl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jon Gockerman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mitchell Horowitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathleen Lambert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gwynn Long, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Moore, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Rizzieri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keith Sullivan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Cohen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Adam Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Emmons, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patricia Kropf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary Ellen Martin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Pro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mitchell Smith, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Klumpp, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth Mangan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Millenson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manish Sharma, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>July 2011</verification_date>
  <lastchanged_date>July 20, 2011</lastchanged_date>
  <firstreceived_date>September 23, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Paul Richardson, MD</name_title>
    <organization>Dana-Farber Cancer Institute</organization>
  </responsible_party>
  <keyword>Lenalidomide</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>Myeloma</keyword>
  <keyword>Multiple Myeloma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
</clinical_study>
